Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
61 Results for "
pDI
" in MedChemExpress (MCE) Product Catalog:
Products (61)
61 Results for "pDI" in MCE Product Catalog:
8
8 Publications Verification
Cat. No.: HY-W107464
CAS No.: 2457232-14-1
Target:
Research Areas:
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .
6
6 Cited Publications
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
5
5 Cited Publications
Target:
Research Areas:
LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding .
LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells .
3
2
2 Cited Publications
E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .
1
Category:
Infection Microorganisms Antibiotics Resistance Selection Disease Research Antibacterial Disease Research Fields Other Antibiotics
Target:
Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant KD of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .
1
1 Cited Publications
CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .
1
Category:
Infection Microorganisms Antibiotics Disease Research Antibacterial Disease Research Fields Other Antibiotics
Target:
1
1 Cited Publications
3-Methyltoxoflavin is a potent Protein disulfide isomerase (PDI) inhibitor, with an IC50 of 170 nM.
1
1
1 Cited Publications
Cat. No.: HY-P71917
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Cellular thyroid hormone binding protein; Cellular thyroid hormone-binding protein; Collagen prolyl 4 hydroxylase beta; Disulphide Isomerase; DSI; EC 5.3.4.1; ER protein 59; ERBA2L; ERp59; GIT; P4HB; P4Hbeta; p55; pDI; pDIA1; pDIA1_HUMAN; pDIR; PHDB; PO4DB; PO4HB; PROHB; Protocollagen hydroxylase; Thbp;
1
Target:
Research Areas:
ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo .
Cat. No.: HY-N2163
CAS No.: 172760-03-1
Category:
Other Monoterpenes other families Monophenols Terpenoids Other Diseases Phenols Plants Disease Research Fields
Target:
Target:
Research Areas:
KSC-34, a covalent modifier of protein disulfide isomerase A1 (PDIA1), is also a selective and potent a-site inhibitor of PDIA1 with an IC50 of 3.5 μM. KSC-34 displays a 30-fold selectivity for a domain over a′ domain and displays high selectivity for PDIA1 in complex proteomes with minimal engagement of other members of the PDI family . KSC-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Target:
Research Areas:
PDI-IN-3 (compound 16F16) is a protein disulfide isomerase (PDI) inhibitor. PDI-IN-3 inhibits cell viability .
Cat. No.: HY-110172
CAS No.: 1461648-55-4
PDI-IN-1 is a cell-permeable PDI covalent inhibitor with an IC50 of 1.7 μM against bovine PDI. PDI-IN-1 specifically modifies the Cys397 residue at the active site of human PDI, selectively labels endogenous PDI in living mammalian cancer cells, and effectively inhibits PDI-mediated insulin aggregation in vitro. PDI-IN-1 exhibits significant anti-tumor activity and inhibits the growth of various cancer cell lines .
(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .
Cat. No.: HY-170655
Research Areas:
PDI-IN-4 is a highly selective inhibitor of human PDI (IC50=0.48 μM) with no significant cytotoxicity. PDI-IN-4 binds to PDI in a reversible manner, not only forming a covalent bond with the Cys400 residue but also engaging in hydrophobic interactions with other residues. By inhibiting the activation of GPIIb/IIIa, PDI-IN-4 effectively blocks platelet aggregation and thrombus formation. PDI-IN-4 can serve as an important tool reagent for thrombosis-related research .
Cat. No.: HY-163351
Research Areas:
PDI-IN-2 is a highly selective PDI inhibitor. PDI-IN-2 has an IC50 of 0.63-4.01 μM against human PDI, and exhibits higher targeting specificity compared with ERp57 and ERp72. PDI-IN-2 inhibits platelet aggregation induced by U46619, collagen and tumor cells, and also blocks platelet-promoted tumor cell proliferation as well as the growth of multiple myeloma cells. PDI-IN-2 serves as an important tool reagent for research on multiple myeloma and associated thrombosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
